From the Archive

Copeland Capital Management has named Sofia Rosala general counsel and chief compliance officer.

Medical device company GI Dynamics has appointed Brian Callahan to the position of chief compliance officer and executive vice president clinical, regulatory and quality.

The SEC and the topic of “regulatory capture” make a brief but memorable appearance in The Big Short, the Academy Award-winning film based on the best-selling book by Michael Lewis.

Olympus, a global medical device company based in Tokyo, Japan, announced the promotions of two senior level positions in the company’s compliance and legal departments, including a new global chief compliance officer.

U.S. financial services company Ally Financial (previously known as GMAC) has appointed Scott Stengel as general counsel, effective May 31. He will assume the role from William Solomon, who will retire after more than 27 years with the company, effective Sept. 30.

Saudi Aramco, a Saudi Arabian national petroleum and natural gas company, has named Nabeel Al Mansour as general counsel and corporate secretary, effective as of May 1.

Visa has appointed James Hoffmeister, who is currently global corporate controller and chief accounting officer, as principal accounting officer for purposes of the company’s filings with the Securities and Exchange Commission. Hoffmeister will oversee the company’s accounting matters.

Pharmaceutical company Astellas announced several new appointments to its ethics and compliance and U.S. legal departments, effective as of April 25.

It seems to me that if you are actually able to create an online forum of hackers and others that allows you to engage in profitable insider trading, that you might want to keep that on the “down low.”  According to a recently-published interview, the “KickAss Insider Trading Forum” disagrees.

Novartis has named Shannon Klinger as chief ethics and compliance officer and head of litigation, effective as of May 1. She assumes these responsibilities from Eric Cornut, who is retiring at a time when Novartis is facing a criminal investigation amid allegations that it made illegal payments to physcians in South Korea.